Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) EBIAT (2016 - 2025)

Historic EBIAT for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $17.3 million.

  • Amphastar Pharmaceuticals' EBIAT fell 5708.53% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.6 million, marking a year-over-year decrease of 2922.42%. This contributed to the annual value of $159.5 million for FY2024, which is 1597.59% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' EBIAT stood at $17.3 million, which was down 5708.53% from $31.0 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' EBIAT's 5-year high stood at $49.2 million during Q3 2023, with a 5-year trough of $5.0 million in Q1 2021.
  • For the 5-year period, Amphastar Pharmaceuticals' EBIAT averaged around $27.7 million, with its median value being $26.1 million (2023).
  • Per our database at Business Quant, Amphastar Pharmaceuticals' EBIAT soared by 70335.9% in 2021 and then tumbled by 5708.53% in 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' EBIAT (Quarter) stood at $19.8 million in 2021, then skyrocketed by 71.62% to $33.9 million in 2022, then grew by 6.65% to $36.2 million in 2023, then rose by 4.97% to $38.0 million in 2024, then tumbled by 54.3% to $17.3 million in 2025.
  • Its EBIAT was $17.3 million in Q3 2025, compared to $31.0 million in Q2 2025 and $25.3 million in Q1 2025.